Jump to content

Drilldown: Medicines

Pharmacopedia
BrowseCategoriesLog in
Pharmacopedia is being built in public. Pages may be incomplete.About this site

Choose a table:


Medicines > classes : Benzodiazepine or [[:Category:Third-generation neuroleptics|Third-generation neuroleptic]]

Use the filters below to narrow your results.

generic:
Alprazolam (1) · Aripiprazole (1) · Bromazepam (1) · Chlordiazepoxide (1) · Clobazam (1) · Clonazolam (1) · Clorazepate (1) · Diclazepam (1) · Estazolam (1) · Flualprazolam (1) · Flubromazepam (1) · Flubromazolam (1) · Flunitrazepam (1) · Flunitrazolam (1) · Flurazepam (1) · Lormetazepam (1) · Midazolam (1) · Nifoxipam (1) · Nitrazepam (1) · Oxazepam (1) · Pyrazolam (1) · Quazepam (1) · Temazepam (1) · Triazolam (1)
brand:
None (9) · Abilify (oral), Abilify Maintena (monthly IM LAI), Aristada (aripiprazole lauroxil IM LAI), Abilify Asimtufii (bi-monthly IM LAI), Abilify MyCite (digital ingestion sensor) (1) · Dalmane (1) · Doral (1) · Halcion (1) · Lexotan (1) · Librium (1) · Mogadon (1) · Onfi (1) · ProSom (1) · Restoril (1) · Rohypnol (1) · Serax (1) · Tranxene (1) · Versed (1) · Xanax (1)
classes: (Click arrow to add another value)
mechanism:
None (1) · Extremely potent GABAA positive allosteric modulator (1) · GABA-A positive allosteric modulator'"`UNIQ--ref-00000067-QINU`"' '"`UNIQ--vote-00000068-QINU`"' (1) · GABAA positive allosteric modulator (18) · GABAA positive allosteric modulator; low sedation (1) · GABAA positive allosteric modulator; prodrug of desmethyldiazepam (1) · GABAA positive allosteric modulator; very long half-life (1)
uses:
None (22) · '"`UNIQ--vote-0000001D-QINU`"', '"`UNIQ--vote-0000001E-QINU`"', '"`UNIQ--vote-0000001F-QINU`"', '"`UNIQ--vote-00000020-QINU`"', '"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"' (1) · '"`UNIQ--vote-00000069-QINU`"', '"`UNIQ--vote-0000006A-QINU`"', '"`UNIQ--vote-0000006B-QINU`"' (1)
starting dose:
None (22) · 0.25 mg (1) · Schizophrenia/bipolar mania: 10-15 mg PO once daily, target 15-30 mg. MDD adjunct: 2-5 mg/day, target 5-15 mg. Pediatric autism irritability: 2 mg, titrate to 5-15 mg. Maintena LAI: 400 mg IM every 4 weeks after oral overlap (1)
preparations:
None (22) · 0.25 mg, 0.5 mg, 1 mg, 2 mg tablets (immediate-release and orally disintegrating); 0.5 mg, 1 mg, 2 mg, 3 mg extended-release tablets; 1 mg/mL oral concentrate (1) · Tablets 2, 5, 10, 15, 20, 30 mg; ODT 10, 15 mg; oral solution 1 mg/mL; acute IM injection 9.75 mg/1.3 mL; Maintena LAI 300, 400 mg monthly; Aristada LAI 441, 662, 882, 1064 mg (4-8 week dosing); Asimtufii bi-monthly (1)
fda max:
None (22) · 10 mg/d (1) · 30 mg/day (adult schizophrenia); 15 mg/day (MDD adjunct) (1)
routes:
None (22) · intramuscular (acute and long-acting) (1) · Oral (2)
onset:
None (22) · 30-60 min (immediate-release); 1-2 h (extended-release) (1) · Neuroleptic effect emerges over days to weeks; activation symptoms (akathisia, insomnia) often within days (1)
duration:
None (22) · 24 hours (oral); 4-8 weeks (LAI) (1) · 6 h (immediate-release); ~11 h (extended-release) (1)
halflife:
None (22) · 11-13 h (immediate-release); 11-16 h (extended-release) (1) · ~75 hours (long, accumulates over weeks)'"`UNIQ--ref-00000023-QINU`"' (1)
bioavailability:
None (22) · 80-90% oral (1) · ~87% (oral)'"`UNIQ--ref-00000024-QINU`"' (1)
pregnancy:
None (22) · Category D'"`UNIQ--ref-0000006C-QINU`"' (1) · Limited human data; signal for neonatal extrapyramidal symptoms and withdrawal with third-trimester exposure.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)
legal:
None (23) · Schedule IV (US) (1)

Showing below up to 24 results in range #1 to #24.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"